Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Topical Collection "Diagnosis and Management of Autoimmune Hemolytic Anemias"
A topical collection in Journal of Clinical Medicine (ISSN 2077-0383). This collection belongs to the section "Hematology".Viewed by 52620
Interests: autoimmune hemolytic anemias; congenital hemolytic anemias; paroxysmal nocturnal hemoglobimuria(EPN); hematology
Interests: autoimmune hemolytic anemias; congenital hemolytic anemias; paroxysmal nocturnal hemoglobimuria(EPN); primary autoimmune hemolytic anemia (AIHA); hematology
Special Issues, Collections and Topics in MDPI journals
Topical Collection Information
Autoimmune hemolytic anemia (AIHA) is a rare and clinically heterogeneous disease ranging from mild to life-threatening hemolysis. It has been historically recognized as an autoantibody-mediated condition, where warm IgG, cold IgM, or both cause antibody-dependent intra- or extravascular hemolysis. More recently, the role of the final effectors of immune hemolysis, i.e., the complement cascade and the reticuloendothelial system, has gained attention. In addition, the importance of bone marrow compensation has emerged as a pivotal factor, and there is evidence that inadequate reticulocytosis correlates with very severe anemia and worse outcome. These observations have paved the way to novel targeted therapies in combination with current treatments based on steroids, rituximab, and splenectomy.
The clinical picture of AIHA is further complicated by the presence of several underlying conditions including infections, lymphoproliferative neoplasms, autoimmune diseases, immunodeficiencies, and tumors, whose diagnosis may either precede or follow that of AIHA. More recently, AIHA has been associated with bone marrow transplantation and with novel biologic anti-cancer drugs. Furthermore, AIHA presentation and related complications may be risk factors for disease refractoriness and mortality. The importance of assessing the presence of these conditions is crucial, since specific treatments may be required, and the risk of infectious and thrombotic complications may vary depending on the diagnosed condition.Prof. Dr. Wilma Barcellini
Dr. Bruno Fattizzo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- primary autoimmune hemolytic anemia (AIHA)
- AIHA secondary to lymphoproliferative neoplasms
- AIHA secondary to other autoimmune diseases
- AIHA secondary to immunodeficiencies
- direct antiglobulin test
- AIHA therapy
- drug-associated AIHA.
Jump to: 2020
Jump to: 2021